The prescribing information for every PDE5 inhibitor includes warnings about vision and hearing changes. These warnings are real — but they range from common-and-benign to extremely-rare-and-serious. Knowing the difference matters.
Blue Vision (Cyanopsia): Common, Benign
The blue-tinted vision some men notice after taking sildenafil is caused by cross-inhibition of PDE6 — the phosphodiesterase enzyme in retinal photoreceptor cells. PDE6 is involved in processing visual signals, particularly color discrimination.
Sildenafil has the highest PDE6 cross-reactivity of the four PDE5 inhibitors, which is why this effect is most commonly reported with Viagra. At standard doses (50–100mg), approximately 3–11% of users report some degree of color tinting, light sensitivity, or blurred vision. The effect is dose-dependent and temporary — it resolves as the medication clears.
For most men, this is a minor nuisance, not a medical concern. It does not indicate retinal damage. However, men with retinitis pigmentosa (a genetic eye condition involving PDE6 mutations) should use PDE5 inhibitors with caution and ophthalmologic monitoring.
NAION: Extremely Rare, Serious
Non-arteritic anterior ischemic optic neuropathy (NAION) — sudden vision loss in one eye — has been reported in men taking PDE5 inhibitors. The FDA added NAION warnings to all PDE5 inhibitor labels in 2005.
The evidence for a causal link is contested. NAION is more common in men with the same cardiovascular risk factors that cause ED (diabetes, hypertension, hyperlipidemia, smoking). It's possible that PDE5 inhibitors contribute to NAION risk in predisposed individuals, but it's also possible that the association is confounded by shared risk factors.
The incidence is very low — estimated at 2–3 per 100,000 PDE5 inhibitor users per year, compared to about 2–10 per 100,000 in the general population over 50. This makes it impossible to determine whether PDE5 inhibitors truly increase risk or whether the association is coincidental.
Action point: If you experience sudden vision loss in one eye while taking any PDE5 inhibitor, stop the medication and seek immediate ophthalmologic evaluation. If NAION is diagnosed in one eye, PDE5 inhibitor use increases the theoretical risk for the other eye — most ophthalmologists recommend discontinuation.
Sudden Hearing Loss: Extremely Rare
The FDA added sudden sensorineural hearing loss (SSNHL) to PDE5 inhibitor labels in 2007 based on post-marketing reports. The mechanism is unclear — possibly related to PDE5 inhibition in the cochlear vasculature.
Like NAION, the incidence is very low and a causal link hasn't been definitively established. Post-marketing reports number in the dozens across millions of prescriptions.
Action point: If you experience sudden hearing loss or ringing in the ears (tinnitus) after taking a PDE5 inhibitor, stop the medication and see an ENT specialist promptly. Sudden hearing loss is a medical urgency regardless of cause — early steroid treatment can improve outcomes.
Putting It in Perspective
The vision and hearing warnings are included in prescribing information because they represent real, documented events. But the absolute risk is extremely low — far lower than the cardiovascular risks associated with the untreated obesity, diabetes, and hypertension that often accompany ED. The blue-vision effect, while common, is harmless and temporary. The serious events (NAION, SSNHL) are rare enough that they don't change the risk-benefit calculus for the vast majority of men.